SCARLETRED®Vision

CE class I medical device

Published by: SCARLETRED Holding
Downloads
Revenue

Description

Scarletred®Vision Mobile App
The app is developed and tested in clinical trials with medical experts and allows to convert a GCP compliant process in your clinical trial and medical routine applications.
Product features:
- Free Registration
- CE class I medical device
- GCP compliant
- Multi user login
- Anonymous subject allocation
- Normalised image generation
- Easy image management
- Encrypted image transfer
- Skin imaging history
More: https://www.scarletred.com/products
Hide Show More...

Screenshots

SCARLETRED®Vision FAQ

  • Is SCARLETRED®Vision free?

    Yes, SCARLETRED®Vision is completely free and it doesn't have any in-app purchases or subscriptions.

  • Is SCARLETRED®Vision legit?

    Not enough reviews to make a reliable assessment. The app needs more user feedback.

    Thanks for the vote

  • How much does SCARLETRED®Vision cost?

    SCARLETRED®Vision is free.

  • What is SCARLETRED®Vision revenue?

    To get estimated revenue of SCARLETRED®Vision app and other AppStore insights you can sign up to AppTail Mobile Analytics Platform.

User Rating
App is not rated in Chile yet.
Ratings History

SCARLETRED®Vision Reviews

No Reviews in Chile
App doesn't have any reviews in Chile yet.

Store Rankings

Ranking History
App Ranking History not available yet
Category Rankings
Chart
Category
Rank
Top Free
142

SCARLETRED®Vision Competitors

Name
Sensoria Mat
Companion App for Sensoria Mat
Edupression by SOFY GmbH
Eczema App Nia
Therapy and diary
HOLI by nevaro
Eczema Manager
for Atopic Dermatitis
Xplora for Find
Xplora for Find™ SARS­-CoV-­2
Yira.ai
life style,Health, Diet, Stats
Habist: Daily Routine Planner
Build Habits and Todo List
SHSA Conference

SCARLETRED®Vision Installs

Last 30 days

SCARLETRED®Vision Revenue

Last 30 days

SCARLETRED®Vision Revenue and Downloads

Gain valuable insights into SCARLETRED®Vision performance with our analytics.
Sign up now to access downloads, revenue, and more.